Long-Term Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Major Adverse Cardiovascular Events and All-Cause Mortality: A Systematic Review and Bayesian Meta-Analysis of Randomized Controlled Trials
Cardiovascular Science · 2026 · 3 (3) · 10008-10008
DOI: 10.70322/cvs.2026.10008 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Science, 2026. Verfasst von Grover Jahnavi und 7 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Jahnavi, G., Wendy, Y., Anjalee, A., Alice, L., Ragavi, J., Praba, S., David, T., & Timothy, T. (2026). Long-Term Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Major Adverse Cardiovascular Events and All-Cause Mortality: A Systematic Review and Bayesian Meta-Analysis of Randomized Controlled Trials. Cardiovascular Science, 3(3), 10008-10008. https://doi.org/10.70322/cvs.2026.10008
Vancouver
Jahnavi G, Wendy Y, Anjalee A, Alice L, Ragavi J, Praba S, et al. Long-Term Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Major Adverse Cardiovascular Events and All-Cause Mortality: A Systematic Review and Bayesian Meta-Analysis of Randomized Controlled Trials. Cardiovascular Science. 2026;3(3):10008-10008. doi:10.70322/cvs.2026.10008
BibTeX
@article{Jahnavi2026,
author = {Jahnavi, Grover and Wendy, Yao and Anjalee, Amarasekera and Alice, Leung and Ragavi, Jeyamohan and Praba, Sekhar and David, Tian and Timothy, Tan},
title = {Long-Term Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Major Adverse Cardiovascular Events and All-Cause Mortality: A Systematic Review and Bayesian Meta-Analysis of Randomized Controlled Trials},
journal = {Cardiovascular Science},
year = {2026},
volume = {3},
number = {3},
pages = {10008--10008},
doi = {10.70322/cvs.2026.10008}
}
EUVIMED